This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marcus, R. Articles by Quigley, C. A. Search for Related Content PubMed PubMed Citation Articles by Marcus, R. Articles by Quigley, C. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Genetics Home Reference Hazardous Substances DB TESTOSTERONE

The Contribution of Testosterone to Skeletal Development and Maintenance: Lessons from the Androgen Insensitivity Syndrome

Veterans Affairs Medical Center and Department of Medicine, Stanford University (R.M., D.L.), Palo Alto, California 94304; Department of Medicine, University of California-San Diego School of Medicine (D.L.S.), La Jolla, California 92093; Department of Medicine Columbia University College of Physicians and Surgeons (E.S.), New York, New York 10032; Department of Medicine, University of Chicago School of Medicine (M.E.), Chicago, Illinois 60637; and Indiana University (C.A.Q.), Indianapolis, Indiana 46285

Address all correspondence and requests for reprints to: Robert Marcus, M.D., GRECC 182-B, Veterans Affairs Medical Center, 3801 Miranda Avenue, Palo Alto, California 94304.

Although androgen status affects bone mass in women and men, an androgen requirement for skeletal normalcy has not been established. Women with androgen insensitivity syndrome (AIS) have 46,XY genotypes with androgen receptor abnormalities rendering them partially or completely refractory to androgen. Twenty-eight women with AIS (22 complete and 6 high grade partial), aged 11–65 yr, responded to questionnaires about health history, gonadal surgery, and exogenous estrogen use and underwent bone mineral density (BMD) assessment by dual energy x-ray absortiometry. BMD values at the lumbar spine and proximal femur were compared to age-specific female normative values and listed as z-scores. Average height for adults in this cohort, 174 cm (68.5 in.), was moderately increased compared with the average height of adult American women of 162.3 cm, with skewing toward higher values: 5 women exceeded 6 ft in height, and 30% of the 18 adult women with complete AIS exceeded 5 ft, 11 in. in height. The average lumbar spine and hip BMD z-scores of the 6 women with partial AIS did not differ from population norms. In contrast, the average lumbar spine BMD z-score of women with complete AIS was significantly reduced at -1.08 (P = 0.0003), whereas the average value for hip BMD did not differ from normal. When BMD was compared between women who reported good estrogen replacement therapy compliance and those who reported poor compliance, there was a significantly greater deficit at the spine for women with poor compliance (z = -2.15 ± 0.15 vs. -0.75 ± 0.28; P < .0001). Furthermore, hip BMD was also significantly reduced in the noncompliant group (z = -0.95 ± .40). Comparison of BMD values to normative male standards gave z-score reductions (z = -1.81 ± 0.36) greater than those observed with female standards. Because of the high prevalence of tall stature in this study sample, we calculated bone mineral apparent density, a variable that adjusts for differences in bone size. Even for the estrogen-compliant group, bone mineral apparent density z-scores were subnormal at both the spine (z = -1.3 ± 0.43; P < 0.01) and the hip (z = -1.38 ± 0.28; P = 0.017). Six women with complete AIS had sustained cortical bone fractures, of whom 3 reported multiple (>3) fractures. We conclude that even when compliance to exogenous estrogen use is excellent, women with complete AIS show moderate deficits in spine BMD, averaging close to 1 SD from normative means, and that with correction of BMD for bone size, skeletal deficits are magnified and include the proximal femur. The results suggest that severe osteopenia in some women with AIS probably reflects a component of inadequate estrogen replacement rather than androgen lack alone.

This article has been cited by other articles:

				T S Han, D Goswami, S Trikudanathan, S M Creighton, and G S Conway Comparison of bone mineral density and body proportions between women with complete androgen insensitivity syndrome and women with gonadal dysgenesis Eur. J. Endocrinol., August 1, 2008; 159(2): 179 - 185. [Abstract] [Full Text] [PDF]

				K. Venken, R. Bouillon, and D. Vanderschueren Androgens Versus Estrogens: Different Theories About Opposing Actions on Periosteal Bone Expansion IBMS BoneKEy, April 1, 2008; 5(4): 130 - 136. [Abstract] [Full Text] [PDF]

				J.-P. Bonjour and T. Chevalley Pubertal Timing, Peak Bone Mass and Fragility Fracture Risk IBMS BoneKEy, February 1, 2007; 4(2): 30 - 48. [Abstract] [Full Text] [PDF]

				V. Sobel, B. Schwartz, Y.-S. Zhu, J. J. Cordero, and J. Imperato-McGinley Bone Mineral Density in the Complete Androgen Insensitivity and 5{alpha}-Reductase-2 Deficiency Syndromes J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3017 - 3023. [Abstract] [Full Text] [PDF]

				N. A. Sims, K. Brennan, J. Spaliviero, D. J. Handelsman, and M. J. Seibel Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E456 - E462. [Abstract] [Full Text] [PDF]

				D. Vanderschueren, K. Venken, J. Ophoff, R. Bouillon, and S. Boonen Sex Steroids and the Periosteum--Reconsidering the Roles of Androgens and Estrogens in Periosteal Expansion J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 378 - 382. [Abstract] [Full Text] [PDF]

				K. Venken and D. Vanderschueren Dual Mode of Action of Androgens on the Skeleton: Are Androgen Receptor and Estrogen Receptor Activation Equally Important at the Same Time and Place? IBMS BoneKEy, January 1, 2006; 3(1): 15 - 17. [Full Text] [PDF]

				A. Aminorroaya, S. Kelleher, A. J Conway, L. P Ly, and D. J Handelsman Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men Eur. J. Endocrinol., June 1, 2005; 152(6): 881 - 886. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				L. Gennari, R. Nuti, and J. P. Bilezikian Aromatase Activity and Bone Homeostasis in Men J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5898 - 5907. [Abstract] [Full Text] [PDF]

				D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson Androgens and Bone Endocr. Rev., June 1, 2004; 25(3): 389 - 425. [Abstract] [Full Text] [PDF]

				S. Wickman, E. Kajantie, and L. Dunkel Effects of Suppression of Estrogen Action by the P450 Aromatase Inhibitor Letrozole on Bone Mineral Density and Bone Turnover in Pubertal Boys J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3785 - 3793. [Abstract] [Full Text] [PDF]

				J. Compston Local Biosynthesis of Sex Steroids in Bone J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5398 - 5400. [Full Text] [PDF]

				S. Issa, D. Schnabel, M. Feix, L. Wolf, H.-E. Schaefer, D. W. Russell, and H.-U. Schweikert Human Osteoblast-Like Cells Express Predominantly Steroid 5{alpha}-Reductase Type 1 J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5401 - 5407. [Abstract] [Full Text] [PDF]

				B. L. Riggs, S. Khosla, and L. J. Melton III Sex Steroids and the Construction and Conservation of the Adult Skeleton Endocr. Rev., June 1, 2002; 23(3): 279 - 302. [Abstract] [Full Text] [PDF]

				S. Khosla, L. J. Melton III, and B. L. Riggs Estrogen and the Male Skeleton J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1443 - 1450. [Abstract] [Full Text] [PDF]

				A. M. Matsumoto Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99. [Full Text]

				C. A. Quigley The Postnatal Gonadotropin and Sex Steroid Surge--Insights from the Androgen Insensitivity Syndrome J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 24 - 28. [Abstract] [Full Text] [PDF]

				S. C. Manolagas and S. Kousteni Perspective: Nonreproductive Sites of Action of Reproductive Hormones Endocrinology, June 1, 2001; 142(6): 2200 - 2204. [Full Text] [PDF]

				G. M Prelevic Osteoporosis in men J R Soc Med, January 12, 2001; 94(12): 620 - 623. [Full Text] [PDF]

				P. Szulc, F. Munoz, B. Claustrat, P. Garnero, F. Marchand, F. Duboeuf, and P. D. Delmas Bioavailable Estradiol May Be an Important Determinant of Osteoporosis in Men: The MINOS Study J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 192 - 199. [Abstract] [Full Text]

				A. B. Wisniewski, C. J. Migeon, H. F. L. Meyer-Bahlburg, J. P. Gearhart, G. D. Berkovitz, T. R. Brown, and J. Money Complete Androgen Insensitivity Syndrome: Long-Term Medical, Surgical, and Psychosexual Outcome J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2664 - 2669. [Abstract] [Full Text]